What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Read original at benzingaStocks · News reference
Lake Street analyst Thomas Flaten downgrades Personalis (NASDAQ:PSNL) from Buy to Hold and announces $16.25 price target.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Read original at benzingaOn August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Department of Veterans Affairs (VA) for the VA's Million Veteran Program (VA MVP). The new task order is effective on
Read original at benzingaFiled: 2026-08-20 AccNo: 0001193125-26-359300 Size: 156 KB Item 8.01: Other Events
Read original at edgarTreasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as gold soars.
Read original at benzinga